A case-matched study of toxicity outcomes after proton therapy and intensity-modulated radiation therapy for prostate cancer

Cancer

Volumn 121, Issue 7, 2015, Pages 1118-1127

  Fang, Penny ^a   Mick, Rosemarie ^b   Deville, Curtiland ^a   Both, Stefan ^a   Bekelman, Justin E ^a   Christodouleas, John P ^a   Guzzo, Thomas J ^b   Tochner, Zelig ^a   Hahn, Stephen M ^a   Vapiwala, Neha ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

gastrointestinal toxicity; genitourinary toxicity; intensity modulated radiation therapy; prostate cancer; proton therapy

Indexed keywords

ACUTE TOXICITY; ADULT; AGED; ARTICLE; BLADDER; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSIMETRY; FOLLOW UP; GASTROINTESTINAL TOXICITY; GENITOURINARY TOXICITY; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROTON THERAPY; RADIATION COLITIS; RADIATION INJURY; RADIATION PROCTOPATHY; RECTUM; RISK REDUCTION; TOXICITY; UNIVARIATE ANALYSIS; URINE RETENTION; UROGENITAL TRACT DISEASE; ADVERSE EFFECTS; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; COMPLICATION; GASTROINTESTINAL DISEASES; MALE UROGENITAL DISEASES; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOMETRY; RADIOTHERAPY DOSAGE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MALE UROGENITAL DISEASES; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; PROTON THERAPY; RADIATION INJURIES; RADIOMETRY; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84925357063     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29148     Document Type: Article

References (24)

1. Slater JD, Rossi CJ, Yonemoto LT, et al. Conformal proton therapy for early-stage prostate cancer. Urology. 1999; 4295: 978-984.
2. Hoppe B, Henderson R, Mendenhall WM, Nichols RC, Li Z, Mendenhall NP,. Proton therapy for prostate cancer. Oncology (Williston Park). 2011; 25: 644-650, 652.
3. Dinan M, Robinson T, Zagar T,. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012; 82: e781-e786.
4. Fowler J,. What can we expect from dose escalation using proton beams? Clin Oncol. 2003; 15: S10-S15.
5. Vargas C, Fryer A, Mahajan C, et al. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 744-751.
6. Sheets NC, Goldin GH, Meyer A, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012; 307: 1611-1620.
7. Yu JB, Soulos PR, Herrin J, et al. Proton versus intensity-modulated radiotherapy for prostate cancer: patterns of care and early toxicity. J Natl Cancer Inst. 2013; 105: 25-32.
8. Deville C, Both S, Bui V, et al. Acute gastrointestinal and genitourinary toxicity of image-guided intensity modulated radiation therapy for prostate cancer using a daily water-filled endorectal balloon [serial online]. Radiat Oncol. 2012; 7: 76.
9. Meyer J, Bluett J, Amos R, et al. Spot scanning proton beam therapy for prostate cancer: treatment planning technique and analysis of consequences of rotational and translational alignment errors. Int J Radiat Oncol Biol Phys. 2010; 78: 428-434.
10. Jones D, Suit H, Akine Y. International Commission on Radiation Units and Measurements Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy. Bethesda, MD: International Commission on Radiation Units and Measurements; 2007.
11. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003; 13: 176-181.
12. Wei JT, Dunn RL, Litwin MS, Sandler HM, Sanda MG,. Development and validation of the Expanded Prostate Cancer Index Composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000; 56: 899-905.
13. Rubin DB,. Matched Sampling for Causal Effects. Cambridge, UK: Cambridge University Press; 2006.
14. Mendenhall NP, Li Z, Hoppe BS, et al. Early outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2012; 82: 213-221.
15. Mayahara H, Murakami M, Kagawa K, et al. Acute morbidity of proton therapy for prostate cancer: the Hyogo Ion Beam Medical Center experience. Int J Radiat Oncol Biol Phys. 2007; 69: 434-443.
16. Nihei K, Ogino T, Onozawa M, et al. Multi-institutional phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys. 2011; 81: 390-396.
17. Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 1124-1129.
18. Pugh TJ, Munsell MF, Choi S, et al. Quality of life and toxicity from passively scattered and spot-scanning proton beam therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2013; 87: 946-953.
19. Eade TN, Horwitz EM, Ruth K, et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008; 71: 338-345.
20. De Meerleer GO, Fonteyne VH, Vakaet L, et al. Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control. Radiother Oncol. 2007; 82: 160-166.
21. Feng M, Hanlon AL, Pisansky TM, et al. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 68: 1417-1423.
22. Gray PJ, Paly JJ, Yeap BY, et al. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013; 119: 1729-1735.
23. Hoppe B, Michalski J, Mendenhall N,. Comparative effectiveness study of patient reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer. 2014; 120: 1076-1082.
24. Deville C, Ben-Josef E, Vapiwala N,. Radiation therapy modalities for prostate cancer [letter]. JAMA. 2012; 308: 450; author reply 451-452.